Abstract
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have